Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
Bo Fu, Wei Long, Ying Zhang, Aifeng Zhang, Fengqin Miao, Yuqing Shen, Ning Pan, Guangming Gan, Fang Nie, Youji He, Jianqiong Zhang, Gaojun Teng
文献索引:Sci. Rep. 5 , 8029, (2015)
全文:HTML全文
摘要
Novel molecularly targeted agents that block the development and metastasis of human brain metastatic breast cancer hold great promise for their translational value. In this study, we constructed a novel targeting composite peptide BRBP1-TAT-KLA comprising of three elements: a brain metastatic breast carcinoma cell (231-BR)-binding peptide BRBP1, a cell penetrating peptide TAT, and a proapoptotic peptide KLA. This composite peptide efficiently internalized in 231-BR cells and consequently induced mitochondrial damage and cellular apoptosis. Exposure of 231-BR cells to BRBP1-TAT-KLA significantly decreased cell viability and increased apoptosis compared with the cells treated with the control peptides. In vivo relevance of these findings was further corroborated in the 231-BR tumor-bearing mice that demonstrated significantly delayed tumor development and metastasis following administration of BRBP1-TAT-KLA compared with those treated with TAT-KLA alone. Interestingly, BRBP1-TAT-KLA inhibited the formation of both large and micro-metastases, while TAT-KLA alone failed to significantly reduce micro-metastases in the breast cancer brain metastasis mice. BRBP1-TAT-KLA selectively homed to the tumors in vivo where it induced cellular apoptosis without significant toxicity on non-tumor tissues. Our findings therefore demonstrated the enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA, providing insights toward development of a potential therapeutic strategy for brain metastatic breast cancer.
相关化合物
相关文献:
2015-02-20
[Oncotarget 6(5) , 2604-14, (2015)]
2014-01-01
[PLoS ONE 9(12) , e116152, (2014)]
2015-05-01
[Biomaterials 51 , 1-11, (2015)]
2015-04-01
[J. Pineal Res. 58(3) , 310-20, (2015)]
2015-04-22
[J. Ethnopharmacol. 164 , 265-72, (2015)]